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Abstract: The retinal pigment epithelial (RPE) cell monolayer forms the outer blood–retinal barrier
and has a crucial role in ocular pharmacokinetics. Although several RPE cell models are available,
there have been no systematic comparisons of their barrier properties with respect to drug permeability.
We compared the barrier properties of several RPE secondary cell lines (ARPE19, ARPE19mel, and
LEPI) and both primary (hfRPE) and stem-cell derived RPE (hESC-RPE) cells by investigating
the permeability of nine drugs (aztreonam, ciprofloxacin, dexamethasone, fluconazole, ganciclovir,
ketorolac, methotrexate, voriconazole, and quinidine) across cell monolayers. ARPE19, ARPE19mel,
and hfRPE cells displayed a narrow Papp value range, with relatively high permeation rates (5.2–26 ×
10−6 cm/s. In contrast, hESC-RPE and LEPI cells efficiently restricted the drug flux, and displayed
even lower Papp values than those reported for bovine RPE-choroid, with the range of 0.4–32 cm−6/s
(hESC-RPE cells) and 0.4–29 × 10−6 cm/s, (LEPI cells). Therefore, ARPE19, ARPE19mel, and hfRPE
cells failed to form a tight barrier, whereas hESC-RPE and LEPI cells restricted the drug flux to a
similar extent as bovine RPE-choroid. Therefore, LEPI and hESC-RPE cells are valuable tools in ocular
drug discovery.
Keywords: retinal pigment epithelium; outer blood–retinal barrier; cell models; drug permeation;
differentiation; tight junctions; ocular drug delivery
1. Introduction
The retinal pigment epithelium (RPE) located in the posterior eye between the neural retina
and choroidal circulation is essential for vision [1]. The RPE cell monolayer maintains the health of
photoreceptors by regulating nutrient transport to and removing metabolic waste products from the
subretinal space. Each day, the RPE cells also phagocytose shed photoreceptor outer segments, an
important part of photoreceptor renewal. The RPE forms the outer blood-retinal barrier by forming
tight junctions between the cells. This restricting barrier prevents the entry of xenobiotics into the
eye, but also clinically useful drugs from the systemic blood circulation. In terms of intravitreal drug
administration, RPE permeation is the main elimination route for small molecular-weight drugs [2];
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however, it efficiently restricts macromolecular elimination, which means that these compounds have
a longer elimination half-life in the vitreous [2,3]. The passage of drugs from the systemic circulation
is restricted by the RPE, and thus only compounds with a high potency and/or selective targeting or
a very wide therapeutic window can be administered systemically to treat retinal disorders. Ocular
diseases, especially age-related macular degeneration, are becoming more common as the population
ages [4]. These diseases represent a major burden for healthcare systems and discomfort for the
patients. Ocular drug development against these retinal diseases is an area in which there is extensive
research, but these programs demand reliable animal, tissue, and cell models, in order to improve the
clinical relevance of early drug development.
Permeation across the RPE cell layer needs to be investigated when the ocular pharmacokinetics
of new chemical entities is evaluated. The rabbit has been the most commonly used species in ocular
pharmacokinetic studies [5,6]; however, simpler models, such as cells or isolated tissue sheets, are
needed in early drug discovery when large numbers of molecules are screened. Currently, ex vivo
models consisting of isolated RPE-choroid tissue sheets mounted in Ussing chambers are considered
the most reliable outer blood–retinal barrier models in drug permeation studies [7]. The RPE-choroid
tissue is usually isolated from the eyes of farm animals (porcine or bovine tissue) [2,8,9] as their tissue
availability is better than that from humans. Due to the larger size of the eye, especially bovine eyes, the
tissue extraction from these animals is easier than is the case in rabbits. However, tissue-sheet isolation
from any species can be technically challenging and depending on the location of the abattoir or animal
facility, the availability of freshly isolated eyes with a good tissue integrity can also be challenging.
RPE cells cultured on filter supports provide an alternative to isolated tissue sheets in permeation
experiments. Several RPE cell models are available, with each having their own strengths and
weaknesses. Human primary RPE cells are widely used in retinal biology studies, but they are rarely
used in drug discovery. Due to the poor availability of adult human RPE cells, human fetal RPE
cells (hfRPE) have been the most commonly used human primary RPE cell model. However, drug
permeation across the primary RPE cells has not been reported.
The continuously growing human RPE cell line, ARPE19 [10], is the most widely used RPE model
in the ocular drug discovery field, but it is leakier than bovine RPE-choroid [9,11]. The culture conditions
and the phenotype of ARPE19 vary between laboratories, and the long differentiation required in
specialized culture conditions is not ideal for high throughput screening. Another shortcoming of
APRE19 cells is their lack of pigment - the native RPE is heavily pigmented and pigment binding is
also a major factor in ocular pharmacokinetics, affecting both the drug distribution and retention in
ocular tissues [12–15].
We have recently established two novel RPE cell models: ARPE19mel [16] and LEPI cells [17],
which have advantageous properties in drug uptake and permeation experiments, respectively.
ARPE19mel cells are artificially re-pigmented ARPE19 cells; the regular, non-pigmented ARPE19 cells
are supplemented with functional melanosomes isolated from porcine RPE [18], leading to spontaneous
phagocytosis and internalization of the pigmented organelles [16]. This cell model is valuable in studies
focusing on the quantitative effects of pigmentation, such as drug uptake. LEPI cells, on the other hand,
have spontaneously arisen from regular ARPE19 cultures. They have a distinct cobblestone morphology,
rapid differentiation and doubling rates, and RPE-specific protein expression [17]. Importantly, we
have previously demonstrated that this cell model reliably demonstrates the impact of permeant
lipophilicity on membrane permeability and displays improved barrier properties by forming an even
tighter barrier than the RPE-choroid [17].
In addition to clinical cell replacement therapy applications [19], the RPE cells differentiated from
human embryonic (hESC) or human-induced pluripotent stem cells (hiPSC) are valuable in retinal
research as they display a mature RPE phenotype after differentiation [20–24]. However, there is rather
limited knowledge regarding the compound permeation of small molecular-weight compounds across
hESC-RPE cells [25,26], and therefore, the applicability of hESC-RPE in early drug development is
still unclear. Even though this cell model is considered to have perhaps the most appropriate RPE
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characteristics in culture, it has rarely been used in retinal drug research as cell differentiation is
demanding and time consuming.
In summary, several RPE cell models are widely used in different fields of retinal research,
but their barrier properties focusing on drug permeation have not been systematically compared
within the same laboratory. In this paper, we present the permeation characteristics of nine small
molecular-weight drugs with varying lipophilicities (logD7.4 values ranging from −5.1 to 1.92) across
ARPE19, ARPE19mel, LEPI, hfRPE, and hESC-RPE cell monolayers. Importantly, in this study, we
compared the obtained apparent permeation coefficients (Papp) to the values recently obtained in our
laboratory in an ex vivo bovine RPE-choroid model [2].
2. Materials and Methods
2.1. Cell Culture
ARPE19 and LEPI cells. ARPE19 cells (American Type Culture Collection, ATCC, Manassas, VA,
USA, product CRL-2302) and LEPI cells [17] were maintained in our laboratory in DMEM/F-12 medium
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (FBS, Gibco,
Thermo Fisher Scientific, Waltham, MA, USA), 1% penicillin-streptomycin, and 2 mM L-glutamine
(both products of Euroclone, Pero, Italy). The cells were seeded onto 1.12 cm2 polyester filters with a
0.4 µm pore size (3460-Clear Transwells, Corning Inc., Corning, NY, USA) at 160,000 cells/cm2, and
cultured for 4 weeks in DMEM-F12 supplemented with 1% FBS, 1% penicillin-streptomycin, and 2 mM
L-glutamine, before the experiments.
ARPE19mel cells. We have recently published a detailed description and characterization of
re-pigmented ARPE19mel cells [16]. In the filter-culture format of ARPE19mel cells, the cells (ARPE19)
were seeded onto filters as described above, and on the following day after seeding, functional
melanosomes isolated from porcine RPE [18] were added to the growth medium, in the apical
compartment. The pigment amount was quantified before the addition to achieve a melanosome
amount equal to 1300 pg melanin/cell. This melanin content is similar to that present in intact porcine
RPE [16]. The melanin amount was determined by an absorbance measurement (at 595 nm, Wallac
Victor2 1420 Multilabel counter, Perkin Elmer, MA, USA) utilizing isolated porcine RPE melanin
standards (0.00–2.00 µg melanin/µL) [16,27]. Similar to the situation with regular ARPE19 cells, the
ARPE19mel cells were cultured for 4 weeks before the experiments, in the same growth medium
mentioned above.
hfRPE cells. The hfRPE cells were purchased from ScienCell (HRPEpiC cells, #6540 ScienCell,
Carlsbad, CA, USA). The cells were expanded as reported previously [28], and seeded at a high density
(200,000 cells/cm2) onto 1.12 cm2 Corning Transwell polyester inserts (3460-Clear Transwells, Corning
Inc., Corning, NY, USA) at passage 3. The cells were cultured in EpiCM medium for 2 weeks before
the permeation experiments (#4101, ScienCell, Carlsbad, CA, USA). We have previously provided a
detailed characterization of these cells [28].
All the cells were cultured at +37 ◦C in 5% CO2, with the medium being replaced three times
a week.
hESC-RPE cells. The hESC-RPE cells were differentiated from two genetically distinct hESC lines:
Regea08/017 and Regea08/023. The derivation and characterization of the lines have been reported
previously in [29]. Human ESCs were cultured on a Biolaminin 521 matrix (Biolamina, Sundbyberg,
Sweden) in Essential 8 Flex Medium (Thermo Fisher Scientific, Waltham, MA, USA), as described
in [23]. During RPE differentiation, hESCs were detached to make a single cell suspension with
the TrypLE™ Select Enzyme (Tryple, Thermo Fisher Scientific, Waltham, MA, USA) and transferred
to Corning® Costar® Ultra-Low attachment plates (Corning Inc., Corning, NY, USA) in RPEbasic
medium containing KnockOut™ Dulbecco’s modified Eagle’s Medium supplemented with 15%
KnockOut™ Serum Replacement, 2 mM GlutaMAX™, 1% MEM non-essential amino acids, 0.1 mM
2-mercaptoethanol, and 50 U/mL penicillin-streptomycin (all from Gibco, Thermo Fisher Scientific,
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Waltham, MA, USA). Embryoid body (EB) formation was induced by overnight induction with 10 µM
blebbistatin (Sigma-Aldrich, St. Louis, MO, USA). For the following 2 days, EBs were allowed to
undergo spontaneous differentiation in RPEbasic medium and on day 4, the EBs were plated down to
0.75 µg/cm2 LN-521 and 10 µg/cm2 human placental collagen type IV (col IV; Sigma-Aldrich, St. Louis,
MO, USA) coating in RPEbasic medium. The medium was subsequently changed three times each
week. After 30–45 days of differentiation, pigmented foci were selected with a scalpel, dissociated
with Tryple, and re-plated in culture wells coated with LN-521 and col IV (RPE passage 1). Forty-five
days later, the hESC-RPE was again re-plated (RPE passage 2) and then a further 9 days later, the
hESC-RPE cells were frozen and subsequently thawed to final culture passage 3 in Corning® Matrigel®
Matrix-coated (44 µg/cm2, cat. 356231, Corning Inc., Corning, NY, USA) PET inserts with a 1 µm pore
size (cat. 83.3932.101 Sarstedt), with 250,000 cells/cm2. The hESC-RPE cells were cultured for 62 days
prior to the permeation studies. The success of hESC-RPE cell differentiation was confirmed in detailed
experiments; the RPE-specific properties of the differentiated cells are presented in Supplementary
material in Figure S1 (characterization performed with the same procedures as described earlier in [23]).
Tampere University has the approval of the National Supervisory Authority for Welfare and
Health (Valvira, Dnro 1426/32/300/05) to conduct research on human embryos. Tampere University also
has supportive statements from the Ethical Committee of the Pirkanmaa Hospital District to derive,
culture, and differentiate hESC lines (Skottman/R05116). No new hESC lines were derived in this study.
2.2. Permeation Studies
The permeation characteristics of aztreonam, ciprofloxacin, fluconazole, ganciclovir, ketorolac,
methotrexate, quinidine, and voriconazole (Table 1) were evaluated as a cassette mix in both
apical-to-basolateral (outward) and basolateral-to-apical (inward) directions. The drug concentration
in the donor compartment was either 1 or 10 µg/mL (Table 1 in HBSS-Hepes (10 mM) buffer (pH 7.40)).
The permeation was monitored for 3 h (ARPE19, ARPE19mel, hfRPE, and LEPI cells) or 6 h (hESC-RPE
cells) at + 37 ◦C with low-speed shaking and the samples were collected at 15, 30, 45, 60, 75, 90, 120, 150,
180 (end-point for ARPE19, ARPE19mel, hfRPE, and LEPI cells), 210, 240, 270, 300, 330, and 360 min
(end-point for hESC-RPE cells). The sample volumes were 0.5 mL in the basolateral and 0.2 mL in the
apical compartment in the case of 1.12 cm2 filters and 0.35 mL in the basolateral and 0.1 mL in the
apical compartment in the case of 0.3 cm2 filters.
Table 1. Compound information.
Compound
1 LogD7.4
(Predicted,
ACDLabs)
Molecular
Weight (g/mol)
2 Manufacturer
Exposure
Concentration
(µg/mL)
Aztreonam −4.32 435.4 Fluka 10
Ciprofloxacin −0.29 331.3 BioChemica 1
Dexamethasone 1.92 392.5 Sigma-Aldrich 10
Fluconazole 0.45 306.3 Sigma-Aldrich 1
Ganciclovir −1.61 255.2 Sigma-Aldrich 1
Ketorolac −0.34 255.3 Sigma-Aldrich 1
Methotrexate -5.1 454.4 Fluka 1
Quinidine 1.17 324.4 Sigma-Aldrich 10
Voriconazole 1.21 349.3 Fluka 10
1 Values collected from the ChemSpider database (Royal Society of Chemistry) or from [2]. 2 Manufacturer locations:
Fluka, USA; Biochemica, China; Sigma Aldrich, St. Louis, MO, USA.
The apparent permeation coefficient (Papp in cm/s) was determined with Equation (1) below:
Papp = J/(C0 × A), (1)
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where J is the drug flux (ng/s) in the linear stage, C0 (ng/cm3) is the exposure concentration in the donor
compartment, and A is the area (cm2) of the cell monolayer. The equation was valid if sink conditions
were maintained, i.e., the receiver compartment concentration was below 10% of the concentration in
the donor compartment.
The eﬄux ratios were calculated to determine the directionality of the drug permeation, using the
following Equation (2):
Eﬄux ratio = Papp (apical-to-basolateral)/Papp (basolateral-to-apical). (2)
2.3. Drug Concentration Measurements
The drug concentrations were determined with a liquid chromatograph (Agilent 1290, Agilent
Technologies, Inc., Santa Clara, CA, USA) and a triple-quadrupole mass spectrometer (Agilent 6495;
Agilent Technologies, Inc., Santa Clara, CA, USA) utilizing electrospray ionization in the positive
ionization mode. We have previously described the method development and validation in detail [27,30],
and a similar validation procedure was used in these LC-MS/MS runs.
3. Results
The Papp values, eﬄux ratios, and flux profiles are presented in detail in Supplementary material
(Tables S1 and S2 and Figures S2 and S3).
We observed clear differences among the cell models in their barrier properties. A wide range of
Papp values was observed in LEPI (0.4–29 × 10−6 cm/s) and hESC-RPE (0.4–32 × 10−6 cm/s) cells, similar
to what was previously found in the bovine RPE-choroid that displayed Papp values for these drugs
ranging from 1.4 to 69.2 × 10−6 cm/s (Figure 1A,B) [2]. There were up to 74-fold differences in these
compounds’ Papp values in LEPI cells and 75-fold differences in hESC-RPE cells, demonstrating the
intactness of the cell monolayers. In contrast, the Papp values of ARPE19, ARPE19mel, and hfRPE cells
exhibited a very narrow range, only varying from 2.0 to 3.1-fold between compounds, and the values
were all relatively high (5.2–26 × 10−6 cm/s, Figure 1A,B), reflecting the leakiness of the monolayers.
In addition, the majority of the compounds permeated across ARPE19, ARPE19mel, and hfRPE in the
apical-to-basolateral direction too rapidly to permit reliable Papp determination: the sink conditions
were not maintained after the first hour (Supplementary material).
The lipophilic drug, fluconazole (logD7.4 0.45), had Papp values in a similar range in all cells
(varying between 5.4 and 25 × 10−6 cm/s, Figure 1C,D, Supplementary material), whereas the largest
differences were seen with the hydrophilic compound, methotrexate (Figure 1E,F), with Papp values
varying from 0.4 to 13 × 10−6 cm/s (Figure 1E,F, Supplementary material). Similarly, the Papp values of
two other lipophilic compounds, quinidine (logD7.4 1.17) and voriconazole (logD7.4 1.21), were similar
in all cell models (Figure 1A,B), whereas the more hydrophilic ganciclovir (logD7.4 −1.61) displayed
20-fold differences in its Papp values (range of 0.9–20 × 10−6 cm/s, Supplementary material).
Outward permeation values of methotrexate and ganciclovir were 4.4- and 2.9-fold higher,
respectively, than inward permeation across the hESC-RPE cell line Regea08/017. Similarly, eﬄux ratios
greater than 2 were observed for aztreonam (4.8), ciprofloxacin (3.9), ganciclovir (2.7), ketorolac (3.1),
and methotrexate (3.0) across LEPI cells, i.e., evidence for a preference for the apical-to-basolateral
(outward) direction (Table 2).
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wide range of Papp values, similar to the situation in the bovine RPE-choroid (values from [2]). Papp
values of the lipophilic drug fluconazole were similar among all the studied RPE models, indicating
transport via a passive transcellular permeation route (C,D). The largest differences were observed in
the permeation of the hydrophilic compound methotrexate (E,F), which displayed high permeation
across ARPE19, ARPE19mel, and hfRPE cells, whereas in hESC-RPE cells, LEPI cells, and bovine
RPE-choroid, its permeation was restricted more efficiently. n = 2–9, see Supplementary material
for details. Abbreviations: n.a., not applicable (drug flux was too rapid for reliable Papp value
determination: more than 10% of the compound permeated within 60 min).
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Table 2. Eﬄux ratios of the studied compounds in tight RPE barriers.
Compound LEPI hESC-RPE(Regea08/017)
hESC-RPE
(Regea08/023)
Bovine
RPE-Choroid 1
Aztreonam 4.8 n.a. n.a. 1.2
Ciprofloxacin 3.9 1.9 1.1 6.7
Dexamethasone 1.1 n.a. n.a. n.d.
Fluconazole 1.5 1.1 1.1 1.2
Ganciclovir 2.7 2.9 1.3 1.5
Ketorolac 3.1 1.8 1.3 14.5
Methotrexate 3.0 4.4 1.8 2.1
Quinidine n.a. 0.9 0.7 n.a.
Voriconazole n.a. 1.1 1.0 1.2
1 Values collected from [2]. n.a., Papp value could not be calculated due problems in analytics (aztreonam) or rapid
drug flux (dexamethasone, quinidine, and voriconazole). n.d., not determined.
Compounds with a high affinity for melanin, i.e., ciprofloxacin and quinidine, displayed lag times
of 100 and 200 min, respectively, in their permeation across hESC-RPE cells in the inward direction
(Figure 2A,B). In the case of ciprofloxacin, the lag time of 100 min was similar to that present in
the bovine RPE-choroid (Figure 2B). The flux profiles of ciprofloxacin and quinidine differed among
ARPE19 and ARPE19mel cells (Figure 2C,D). These cells are otherwise identical, but ARPE19mel cells
contain melanosomes [16].
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min in its permeation across the hESC-RPE cell layers, but no clear lag time was evident in bovine 
RPE-choroid (inset). (B) A permeation lag-time of approximately 100 min was detected for 
ciprofloxacin in hESC-RPE cells, which was similar to that present in bovine RPE-choroid (inset). Flux 
profiles of (C) quinidine and (D) ciprofloxacin differed between the non-pigmented ARPE19 and re-
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4. Discussion
We performed a quantitative and systematic comparison of RPE cell model barrier functions by
investigating drug flux across the cell monolayers of ARPE19, ARPE19mel, hfRPE, LEPI, and hESC-RPE
cells. Our results clearly indicate that the hESC-RPE and LEPI cells restrict the drug permeation to a
similar extent to that encountered in the ex vivo RPE model (bovine RPE-choroid), whereas ARPE19,
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ARPE19mel, and hfRPE cells display a leaky barrier, as indicated by the rapid drug flux and high Papp
values. An overview of the cell model properties is presented in Table 3 below.
Table 3. Overview of the RPE cell model properties.
Cell Model CultureConditions
Tight
Junction
Protein
Expression
Pigmentation
Barrier
Properties:
Conclusions
of this
Study
Assays in
Which the Cell
Model can be
Utilized in
Early Drug
Discovery
Cell lines
ARPE19
simple to
demanding;
variation between
laboratories
yes no leaky Drug uptake,active transport
ARPE19mel simple yes
can be
controlled;
from low to
heavy
leaky
Drug uptake:
quantitative
effects of
pigmentation
LEPI simple yes no tight Drug uptakeand permeation
Primary RPE cells
hfRPE simple yes low/modest leaky Drug uptake,active transport
Stem-cell based RPE cells
hESC-RPE
demanding; long
differentiation time,
requires
specialized
conditions and
expensive
supplements
yes heavy tight Drug uptakeand permeation
Permeation across the bovine RPE-choroid was recently investigated in our laboratory with
eight small molecular-weight drugs: aztreonam, ciprofloxacin, fluconazole, methotrexate, ketorolac,
quinidine, and voriconazole. The Papp values displayed a wide range: there was a 5-fold difference
between the highly permeating lipophilic voriconazole and the slowly permeating hydrophilic
aztreonam [2]. We observed a similarly wide range in the Papp values of hESC-RPE and LEPI cells,
whereas the range of hfRPE, ARPE19, and ARPE19mel cells was narrow (Figure 1A,B). Because all the
studied compounds displayed good permeation across the hfRPE, ARPE19, and ARPE19mel, these
cells do not possess a tight barrier able to restrict drug permeation. The clearest differences between
the leaky (hfRPE, ARPE19, and ARPE19mel) and tight (bRPE-choroid, hESC-RPE, and LEPI) epithelial
barriers were seen with the hydrophilic compounds ganciclovir and methotrexate, which utilize the
paracellular route (Figure 1A,B). Paracellular diffusion of these compounds is rapid across ARPE19,
ARPE19mel, and hfRPE, indicating that their tight junctions are not able to efficiently restrict the
drug flux.
The leakiness of the ARPE19 monolayer was an expected result: in the earlier work of Mannermaa
et al. (2010), the cell line displayed a 7.6 times higher Papp value of hydrophilic 6-carboxyfluorescein,
utilized as a paracellular marker, than bovine RPE-choroid [9,11]. However, ARPE19 cells reproduced
the effect of a permeant size and lipophilicity on membrane permeation in that study, and therefore,
the cell line can be a valuable tool in ocular drug research. In addition, ARPE19 cells display a
similar transporter expression profile to primary RPE cells [28], suggesting that both of these cell
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models can be utilized in drug uptake studies. Furthermore, these leaky cell models might be suitable
for predicting macromolecule or nanoparticle permeation across the RPE. It is possible that hfRPE
and ARPE19 cells would develop a tighter barrier and a longer culture time in specialized culture
conditions. ARPE19 cells can differentiate into a phenotype similar to adult RPE [31–33]; however,
this can take several weeks or even months of differentiation. It should be noted that the addition of
supplements (growth factors, sodium pyruvate, and amino acids) to ARPE19 growth media can lead
to the creation of a tighter barrier due to multilayering of the cells instead of maturation of the tight
junctions [11]. We observed the multilayering of hfRPE cells when an extracellular matrix (laminin
or fibronectin) was used (data not shown), while culturing hfRPE cells on un-coated culture dishes
resulted in a cell monolayer with an RPE-specific phenotype within 2 weeks [28,34]. In more advanced
models, such as hESC-RPE, extracellular matrix coatings are routinely used. Human ESC-RPE cell
differentiation, maturation, and barrier formation take several weeks in vitro and the extracellular
matrix coating affects the barrier properties of the developing hESC-RPE cells [35]. Simple culture
conditions were selected in this study for hfRPE cells and ARPE19-based models, since LEPI cells are
able to differentiate rapidly, without the need for specialized culture conditions [17].
Stem-cell-derived RPE cells have been proven to differentiate into a phenotype that resembles
adult RPE cells: the cells phagocytose photoreceptor outer segments; express various RPE-specific
proteins; and display polarization, a high level of pigmentation, a polarized secretion of growth factors,
and a tight barrier, as indicated by their tight junction protein expression and high transepithelial
electrical resistance (TEER) [21,23,24]. The hESC-RPE cells were expected to form a tight barrier
against drug diffusion as the permeation of 6-carboxyfluorescein was previously reported to be only
slightly higher across hESC-RPE monolayers in comparison to bovine RPE-choroid (5–6-folds) [9,25].
This study confirmed that hESC-RPE cells display appropriate barrier characteristics against drug
flux: the Papp values had a wide range and the cells restricted drug flux more efficiently than bovine
RPE-choroid (Figure 1). The ARPE19-derived cell line LEPI restricted the drug flux to a similar extent
as hESC-RPE cells, forming a tight epithelial barrier. We have previously characterized this cell line in
detail; the cells display RPE-specific protein expression and functions [17].
The lipophilic compounds (fluconazole, voriconazole, and quinidine) displayed the highest
permeation rates across bovine RPE-choroid, hESC-RPE, and LEPI cells, with similar Papp values
in ARPE19 models and hfRPE cells (Figure S1, Supplementary material). This indicates that the
permeation mechanism of fluconazole, quinidine, and voriconazole is transcellular passive permeation,
as expected for lipophilic compounds. This finding highlights the importance of having appropriate
model compounds when evaluating barrier formation: lipophilic compounds utilizing transcellular
passive diffusion do not necessarily reveal the leakiness of the cellular barrier.
Directional permeation can be an indication of active transport, and eﬄux ratios outside the
range of 0.5–2 point to the involvement of active transport [36]. We observed directionality in the
permeation of methotrexate and ganciclovir in one of the hESC-derived RPE cell lines (Regea08/017)
(Table 2); however, the eﬄux ratios were modest (4.4 and 2.9, respectively). In the case of LEPI cells,
a directional preference in an outward direction was observed with hydrophilic compounds (aztreonam,
ciprofloxacin, ganciclovir, ketorolac, and methotrexate, Table 2). These eﬄux ratios were also modest,
ranging from 2.7 to 4.8. hESC-RPE and LEPI cells restricted the methotrexate and ganciclovir flux even
more efficiently than bovine RPE-choroid (Figure 1E–F): Papp of methotrexate was 11.4-fold higher in
the basolateral-to-apical direction across bovine RPE-choroid compared to hESC-RPE and LEPI, and the
corresponding difference in ganciclovir Papp values was 6.6–7.4-fold, respectively. The poor permeation
of ganciclovir and methotrexate can be explained by their physicochemical properties: hydrophilic
compounds are not able to cross the cell monolayer transcellularly and tight junctions restrict the
paracellular permeation. However, low permeation in both directions might partly be a consequence
of active eﬄux on both sides of the RPE, and the minor directional differences can be caused by slight
variations in the active transport rates. Ganciclovir is a substrate of MATE1 and methotrexate is a
substrate of several transporter proteins, including MRP1, MRP4, and MRP5. Similarly, hydrophilic
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ketorolac is a substrate for OAT2 and both species differences between humans and cows and possible
differences among the protein expression in human cell models can cause variation in the permeation,
even between tight RPE models. All of the listed transporters have been detected at the protein level in
RPE cell cultures [28,37]. A recent proteomics-based study indicated that these transporters are present
on both RPE surfaces [34]. Passive permeation is expected to be the main permeation mechanism
across the RPE for the majority of compounds, since an excellent correlation was observed between the
physicochemical descriptors (hydrogen bonding and LogD7.4) and both intravitreal clearance [5] and
systemic-to-eye drug transfer [38]. In addition, the impact of active transport in RPE permeation is
expected to be low [39]. Our data supports this conclusion: most of the studied compounds did not
display strong directional preferences, evidence of the predominance of passive permeation.
Differences in pigmentation are not expected to affect the compounds’ Papp values, but the
linear phase in the drug flux across pigmented cells can be delayed in the case of melanin-bound
compounds [9]. This is attributable to their larger intracellular volume of distribution. Ciprofloxacin
and quinidine had dual-phased flux across highly pigmented hESC-RPE cells and bovine RPE-choroid
(Figure 2A,B). Both ciprofloxacin and quinidine are high-melanin binders [27], and the lag times of
120–200 min needed to reach a steady-state in inward permeation can therefore be explained by melanin
binding. The flux profile of quinidine did not show a clear lag time across the bovine RPE-choroid;
however, the permeated amount was negligible (Figure 2A), and the mass balance was incomplete [2],
which can be an indication of intracellular drug accumulation [2,9]. Since ARPE19-based cells had a
leakier barrier, no clear lag time was observed with ARPE19mel cells. However, the flux profile of two
high melanin-binders, i.e., ciprofloxacin and quinidine, is different in ARPE19 and ARPE19mel cells
(Figure 2C,D), whereas the flux profiles of other drugs, all low melanin-binders [27], are similar in
both cell lines (Supplementary material). Overall, non-pigmented cells can be utilized in permeation
experiments as the Papp values are not dependent on the extent of pigmentation (Figure 1A,B).
As pigment binding is a major factor affecting ocular pharmacokinetics [12,13], pigment binding
properties need to be determined in early drug discovery; they can be determined with non-cellular
binding studies [14,27,40] or with re-pigmented ARPE19mel cells [16].
Permeation across the RPE is an important parameter in ocular pharmacokinetics and thus
needs to be screened during early drug development. In addition, realistic permeation values are
crucial in in silico pharmacokinetic models. In this paper, we showed that hESC-RPE and LEPI cells
display appropriate barrier properties against drug flux and are therefore valuable in vitro models in
permeation experiments. Similar to Caco-2 cells and intestinal tissue [41], these RPE cells displayed
even tighter barrier characteristics against drug flux than RPE-choroid tissue mounted in an Ussing
chamber (Figure S1, Supplementary material). This finding is consistent with our earlier report in
which we compared the permeation of beta-blockers across LEPI and bovine RPE-choroid [17]. LEPI
cells are easily differentiated in simple culture conditions, making them a very attractive RPE cell
model for high throughput screening, while advanced stem-cell-based models provide a platform on
which to study permeation in disease-state cells [42].
5. Conclusions
In conclusion, our results reveal clear differences in the barrier function of RPE cell models. While
useful in drug uptake studies, ARPE19-based models and hfRPE cells do not possess an appropriate
barrier to restrict drug flux across the monolayer, whereas hESC-RPE and LEPI cells form a tight barrier
comparable to bovine RPE-choroid. This difference was seen most clearly with hydrophilic compounds.
The advantage of hESC-RPE cells is that they display lag-times with pigment-binding compounds
due to the heavy pigmentation of these cells; however, their maintenance and differentiation are
demanding and time-consuming. LEPI cells, on the other hand, are easily maintained and can be
rapidly expanded and differentiated, making them an advantageous model for the outer blood–retinal
barrier in assays requiring large numbers of cells, although they lack pigments. Overall, LEPI and
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hESC-RPE are clearly suitable outer blood–retinal barrier models for evaluating the permeation of
small molecular-weight compounds.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/2/176/s1:
Supplementary Materials: The characterization of hESC-RPE cultures and Papp values, eﬄux ratios, and flux
profiles for each cell model and studied compound (PDF-file). Figure S1: Human ESC-RPE cells display
characteristic RPE properties prior to the permeation studies; Figure S2: Flux of hydrophilic compounds across
RPE cell models and bovine RPE-choroid; Figure S3: Flux of lipophilic compounds across RPE cell models and
bovine RPE-choroid; Table S1: Apparent permeation coefficients; Table S2: Eﬄux ratios.
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